4.4 Article

Systemic Therapy and Its Surgical Implications in Patients with Resectable Liver Colorectal Cancer Metastases. A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference

Journal

CURRENT ONCOLOGY
Volume 29, Issue 3, Pages 1796-1807

Publisher

MDPI
DOI: 10.3390/curroncol29030147

Keywords

colorectal liver metastases; systemic therapy; chemotherapy; surgery; metastasectomy; adjuvant therapy; CRLM; consensus

Categories

Funding

  1. Pfizer Canada Inc.
  2. Eisai Inc.
  3. IPSEN Biopharmaceutical Canada Inc.
  4. Incyte Biosciences Canada
  5. Bristol-Myers Squibb Canada
  6. Amgen Canada Inc.
  7. AstraZeneca
  8. Viatris
  9. Taiho Pharma Canada Inc.

Ask authors/readers for more resources

The Western Canadian Gastrointestinal Cancer Consensus Conference discussed the use and optimal sequence of systemic therapy in patients with resectable metastatic colorectal cancer. Healthcare professionals from four Western Canadian provinces participated in the conference.
The Western Canadian Gastrointestinal Cancer Consensus Conference (WCGCCC) convened virtually on 4 November 2021. The WCGCCC is an interactive multi-disciplinary conference attended by health care professionals, including surgical, medical, and radiation oncologists; pathologists; radiologists; and allied health care professionals from across four Western Canadian provinces, British Columbia, Alberta, Saskatchewan, and Manitoba, who are involved in the care of patients with gastrointestinal cancer. They participated in presentation and discussion sessions for the purpose of developing recommendations on the role of systemic therapy and its optimal sequence in patients with resectable metastatic colorectal cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available